Loader

Pathways

PathWhiz ID Pathway Meta Data

PW124095

Pw124095 View Pathway
signaling

CB2 Receptor

Homo sapiens
CB2 receptors are located throughout the peripheral nervous system, in immune cells, and in microglial cells within the brain stem. They are closely tied to immune responses, mediating inflammatory responses in the brain and throughout the body. CB2 receptors are G-protein coupled receptors and are especially critical in promoting chemotaxis through the release of chemokines. The main mechanism of action involves inhibiting adenylyl cyclase, which increases the concentration of cAMP in the cell. Through its coupling with G-proteins, CB2 inhibits calcium channels in the cell membrane, disrupting the flow of calcium ions into the cell and can further regulate calcium concentrations when acted upon by anandamide. However, CB2 seems to not have an effect on potassium channels, a marked difference from CB1 receptors. Activation of CB2 receptors also activates MAPK and its associated signalling pathway, which affects translation and transcription especially in relation to mitosis. CB2's most remarkable difference from CB1 is its effect on the release of chemokines. Depending on the ligand binding to it, CB2 can act either to promote or suppress the release of chemokines from the cell, enabling both inflammatory and anti-inflammatory responses. This versatility, combined with CB2's lack of psychotropic effects makes it a promising target for therapeutic treatments of a range of conditions.

PW064729

Pw064729 View Pathway
metabolic

CCM

Escherichia coli

PW122205

Pw122205 View Pathway
protein

CD40L Signalling Pathway

Bos taurus
CD40 is a part of the tumor necrosis factor (TNF) receptor superfamily. When bound to it’s main ligand CD40L, also known as CD154, CD40-CD40L interaction initializes the activation and proliferation of B lymphocytes or results in carcinoma cells apoptosis. CD40 can be expressed on many different cell surfaces such as endothelial cells, fibroblasts, hematopoietic progenitors, platelets, and basal epithelial cells. When combined with the variety of environments CD40 presenting cells can be in, the differing effects resulting from CD40 signalling is vast. However, one characteristic all CD40 mediated signalling has in common is that instead of using kinase to mediate signal transduction, signalling is performed through downstream adapter molecules. Some pathways activated by CD40-CD40L signalling include the activation of nuclear factor-κB, p38 mitogen activated protein kinase, c-Jun-NH2-kinase, signal transducers and activators of transcription, and phosphoinositide 3-kinase pathways. All of which ultimately help regulate alterations in gene expression.

PW122229

Pw122229 View Pathway
protein

CD40L Signalling Pathway

Rattus norvegicus
CD40 is a part of the tumor necrosis factor (TNF) receptor superfamily. When bound to it’s main ligand CD40L, also known as CD154, CD40-CD40L interaction initializes the activation and proliferation of B lymphocytes or results in carcinoma cells apoptosis. CD40 can be expressed on many different cell surfaces such as endothelial cells, fibroblasts, hematopoietic progenitors, platelets, and basal epithelial cells. When combined with the variety of environments CD40 presenting cells can be in, the differing effects resulting from CD40 signalling is vast. However, one characteristic all CD40 mediated signalling has in common is that instead of using kinase to mediate signal transduction, signalling is performed through downstream adapter molecules. Some pathways activated by CD40-CD40L signalling include the activation of nuclear factor-κB, p38 mitogen activated protein kinase, c-Jun-NH2-kinase, signal transducers and activators of transcription, and phosphoinositide 3-kinase pathways. All of which ultimately help regulate alterations in gene expression.

PW122181

Pw122181 View Pathway
protein

CD40L Signalling Pathway

Mus musculus
CD40 is a part of the tumor necrosis factor (TNF) receptor superfamily. When bound to it’s main ligand CD40L, also known as CD154, CD40-CD40L interaction initializes the activation and proliferation of B lymphocytes or results in carcinoma cells apoptosis. CD40 can be expressed on many different cell surfaces such as endothelial cells, fibroblasts, hematopoietic progenitors, platelets, and basal epithelial cells. When combined with the variety of environments CD40 presenting cells can be in, the differing effects resulting from CD40 signalling is vast. However, one characteristic all CD40 mediated signalling has in common is that instead of using kinase to mediate signal transduction, signalling is performed through downstream adapter molecules. Some pathways activated by CD40-CD40L signalling include the activation of nuclear factor-κB, p38 mitogen activated protein kinase, c-Jun-NH2-kinase, signal transducers and activators of transcription, and phosphoinositide 3-kinase pathways. All of which ultimately help regulate alterations in gene expression.

PW090779

Pw090779 View Pathway
protein

CD40L Signalling Pathway

Homo sapiens
CD40 is a part of the tumor necrosis factor (TNF) receptor superfamily. When bound to it’s main ligand CD40L, also known as CD154, CD40-CD40L interaction initializes the activation and proliferation of B lymphocytes or results in carcinoma cells apoptosis. CD40 can be expressed on many different cell surfaces such as endothelial cells, fibroblasts, hematopoietic progenitors, platelets, and basal epithelial cells. When combined with the variety of environments CD40 presenting cells can be in, the differing effects resulting from CD40 signalling is vast. However, one characteristic all CD40 mediated signalling has in common is that instead of using kinase to mediate signal transduction, signalling is performed through downstream adapter molecules. Some pathways activated by CD40-CD40L signalling include the activation of nuclear factor-κB, p38 mitogen activated protein kinase, c-Jun-NH2-kinase, signal transducers and activators of transcription, and phosphoinositide 3-kinase pathways. All of which ultimately help regulate alterations in gene expression.

PW064757

Pw064757 View Pathway
metabolic

CDRS

Homo sapiens

PW146938

Pw146938 View Pathway
drug action

Cedazuridine Drug Metabolism Action Pathway

Homo sapiens

PW176937

Pw176937 View Pathway
drug action

Cefaclor Action Pathway

Escherichia coli
Cefaclor is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Cefaclor exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.

PW144939

Pw144939 View Pathway
drug action

Cefaclor Drug Metabolism Action Pathway

Homo sapiens